TW201141486A - Pharmaceutical composition for treating macular edema - Google Patents

Pharmaceutical composition for treating macular edema Download PDF

Info

Publication number
TW201141486A
TW201141486A TW100112624A TW100112624A TW201141486A TW 201141486 A TW201141486 A TW 201141486A TW 100112624 A TW100112624 A TW 100112624A TW 100112624 A TW100112624 A TW 100112624A TW 201141486 A TW201141486 A TW 201141486A
Authority
TW
Taiwan
Prior art keywords
group
composition
alkoxy
carbon number
fatty acid
Prior art date
Application number
TW100112624A
Other languages
English (en)
Chinese (zh)
Inventor
Yukihiko Mashima
Ryuji Ueno
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Publication of TW201141486A publication Critical patent/TW201141486A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
TW100112624A 2010-04-12 2011-04-12 Pharmaceutical composition for treating macular edema TW201141486A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32333810P 2010-04-12 2010-04-12
US32334210P 2010-04-12 2010-04-12
US32681110P 2010-04-22 2010-04-22
US36294510P 2010-07-09 2010-07-09
US40823710P 2010-10-29 2010-10-29

Publications (1)

Publication Number Publication Date
TW201141486A true TW201141486A (en) 2011-12-01

Family

ID=44798822

Family Applications (2)

Application Number Title Priority Date Filing Date
TW100112624A TW201141486A (en) 2010-04-12 2011-04-12 Pharmaceutical composition for treating macular edema
TW100112738A TW201204366A (en) 2010-04-12 2011-04-12 Ophthalmic composition for treating retinal disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW100112738A TW201204366A (en) 2010-04-12 2011-04-12 Ophthalmic composition for treating retinal disease

Country Status (9)

Country Link
US (2) US20110275711A1 (enExample)
EP (2) EP2558104A4 (enExample)
JP (3) JP5686819B2 (enExample)
KR (2) KR20130099812A (enExample)
CN (2) CN102946883A (enExample)
AR (1) AR080888A1 (enExample)
CA (2) CA2795723A1 (enExample)
TW (2) TW201141486A (enExample)
WO (2) WO2011129457A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2780650A1 (en) * 2009-11-27 2011-06-03 R-Tech Ueno, Ltd. Method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion and a pharmaceutical composition obtained by the method
CN103596572A (zh) * 2011-04-12 2014-02-19 株式会社·R-技术上野 水性眼用组合物
HK1205461A1 (zh) * 2012-02-22 2015-12-18 Trustees Of Tufts College 用於眼部传输治疗剂的组合物和方法
AU2017317129B2 (en) * 2016-08-24 2020-04-30 National Institute Of Biological Sciences, Beijing Entacapone-related compounds to treat macular degeneration
US12702683B2 (en) 2019-01-03 2026-08-11 Mesoblast International Sárl Method for improving visual acuity
EP4667578A3 (en) * 2019-04-03 2026-04-01 REGENXBIO Inc. Gene therapy for eye pathologies
JP7664239B2 (ja) * 2019-10-30 2025-04-17 パフューズ セラピューティクス， インコーポレイテッド エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
CA3168810A1 (en) 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
BR112023022705A2 (pt) 2021-04-30 2024-01-16 Perfuse Therapeutics Inc Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares
WO2023283256A1 (en) 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds
AU2023303408A1 (en) 2022-07-06 2024-12-19 Aligos Therapeutics, Inc. Anti-viral compounds
FI131849B1 (en) * 2024-09-10 2026-01-09 Pixieray Oy METHOD AND OPTICAL DEVICE FOR MONITORING THE USE OF EYE DROPS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU771130B2 (en) * 2000-01-18 2004-03-11 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2003020283A2 (en) * 2001-08-29 2003-03-13 Novartis Ag Method for treating diabetic retinopathy
JP5222462B2 (ja) * 2003-08-21 2013-06-26 スキャンポ・アーゲー 眼科用組成物
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
US20080233053A1 (en) * 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
US20100087540A1 (en) * 2008-10-07 2010-04-08 R-Tech Ueno, Ltd. Pharmaceutical composition

Also Published As

Publication number Publication date
EP2558103A4 (en) 2013-09-25
WO2011129461A1 (en) 2011-10-20
CA2795723A1 (en) 2011-10-20
US20110275715A1 (en) 2011-11-10
US20110275711A1 (en) 2011-11-10
JP2013528563A (ja) 2013-07-11
KR20130050939A (ko) 2013-05-16
JP2013523601A (ja) 2013-06-17
CN102946883A (zh) 2013-02-27
KR20130099812A (ko) 2013-09-06
EP2558104A4 (en) 2013-12-11
JP5686819B2 (ja) 2015-03-18
TW201204366A (en) 2012-02-01
EP2558104A1 (en) 2013-02-20
EP2558103A1 (en) 2013-02-20
JP5878128B2 (ja) 2016-03-08
AR080888A1 (es) 2012-05-16
JP2016026182A (ja) 2016-02-12
CA2795720A1 (en) 2011-10-20
WO2011129457A1 (en) 2011-10-20
CN102933217A (zh) 2013-02-13

Similar Documents

Publication Publication Date Title
TWI298257B (en) Hypotensive lipid and timolol compositions and methods of using same
US20110275711A1 (en) Method for treating macular edema
CN113518619A (zh) 用于治疗眼部新生血管形成的药物组合物
JP2009137971A (ja) 薬剤および薬剤キット
TW201247614A (en) Aqueous ophthalmic composition
TWI403324B (zh) 醫藥組成物
US20120087864A1 (en) Method for diagnosing and/or evaluating retinal disease
TWI501769B (zh) 治療黃斑部病變用組成物
US8889735B2 (en) Method for treating asthenopia
JPWO2006098292A1 (ja) 眼疾患治療剤
TW201102070A (en) Pharmaceutical composition for modulating claudin mediated functions
TW200400039A (en) Method for treating ocular hypertension and glaucoma
TW201347757A (zh) 治療帶有腹瀉之腸躁症之方法
US20170042908A1 (en) Method for treating geographic atrophy associated with age-related macular degeneration
CN105330578A (zh) 一种用于治疗黄斑水肿的化合物及其药物组合物
HK1181675A (en) Pharmaceutical composition for treating macular edema